A
Arnon Nagler
Researcher at Sheba Medical Center
Publications - 1435
Citations - 51740
Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal Article
Adoptive cell therapy for metastatic melanoma patients: pre-clinical development at the Sheba Medical Center.
Michal J. Besser,Avraham J. Treves,Orit Itzhaki,Izhar Hardan,Arnon Nagler,Moshe Z. Papa,Raphael Catane,Eyal Winkler,Bruria Shalmon-Zifroni,Jacob Schachter +9 more
TL;DR: Pre-clinical studies of the TIL technology in a clinical laboratory set-up were performed successfully and this modality is ready for treating metastatic melanoma patients at the Sheba Medical Center's Ella Institute.
Journal ArticleDOI
Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT.
Simone Cesaro,Roberto Crocchiolo,Gloria Tridello,Nina Knelange,Maria Teresa Van Lint,Yener Koc,Fabio Ciceri,Zafer Gulbas,Johanna Tischer,Boris V. Afanasyev,Benedetto Bruno,Luca Castagna,Didier Blaise,Mohamad Mohty,Giuseppe Irrera,J. L. Diez-Martin,Luca Pierelli,Pietro Pioltelli,Mutlu Arat,Mario Delia,Franca Fagioli,Gerhard Ehninger,Mahmoud Aljurf,Angelo Michele Carella,Hakan Ozdogu,Malgorzata Mikulska,Per Ljungman,Arnon Nagler,Jan Styczyński +28 more
TL;DR: The choice of a CMV-seronegative donor did not impair early survival of CMv-seropositive patients with acute leukemia after a first, non T-cell depleted haploidentical HSCT and PT-Cy among this series of 983 consecutive patients.
Journal ArticleDOI
The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
Marie T Rubio,Bipin N. Savani,Myriam Labopin,Emmanuelle Polge,Dietger Niederwieser,Arnold Ganser,Rainer Schwerdtfeger,Gerhard Ehninger,Jürgen Finke,Arnold Renate,Charles Craddock,Nicolaus Kröger,Michael Hallek,Pavel Jindra,Mohamad Mohty,Arnon Nagler +15 more
TL;DR: Reduced intensity conditioned allo-SCT with a 10/10 M-URD remains the preferable option for AML patients above the age of 50 years and the use of a 9/10 or an 8/10 mM-urD in patients not having a fully matched donor represents an alternative therapeutic option that should be compared to other alternative donor transplant strategies.
Journal ArticleDOI
Inverse correlation between HPSE gene single nucleotide polymorphisms and heparanase expression: possibility of multiple levels of heparanase regulation.
Olga Ostrovsky,Michael Korostishevsky,Itay Shafat,Margarita Mayorov,Neta Ilan,Israel Vlodavsky,Arnon Nagler +6 more
TL;DR: It is indicated that rs4693608 and rs4364254 SNPs are involved in the regulation of heparanase expression and provides the basis for further studies on the association between HPSE gene SNPs and disease outcome.
Journal Article
Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience.
Avichai Shimoni,Arnon Nagler +1 more
TL;DR: In this article, the authors discuss emerging data defining the relative toxicities and outcomes after non-myeloablative transplantation in certain settings and their approach to patient selection and post-transplant immune interventions trying to improve overall outcome.